Literature DB >> 14656311

SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats.

Stéphanie Caillé1, Loren H Parsons.   

Abstract

The present experiments tested the hypothesis that the selective CB1 receptor antagonist SR141716A alters heroin self-administration by attenuating heroin-induced increases in nucleus accumbens dopamine levels. SR141716A pretreatment dose-dependently (0.3-3 mg/kg, i.p.) reduced operant heroin self-administration by male Wistar rats under a fixed ratio schedule of reinforcement, and significantly lowered the breaking point of responding for heroin under a progressive ratio schedule of reinforcement. These observations are consistent with recent reports that CB1 receptor inactivation reduces the rewarding properties of opiates. Operant responding for water reinforcement by water-restricted rats was unaltered by these SR141716A doses. Microdialysis tests revealed that heroin self-administration significantly increases interstitial dopamine levels in the nucleus accumbens shell of vehicle-pretreated control rats. However, whereas SR141716A pretreatment dose-dependently reduced heroin self-administration, it did not alter the heroin-associated increase in nucleus accumbens dopamine. These findings suggest that the CB1 antagonist-induced attenuation of heroin reward does not involve dopaminergic mechanisms in the nucleus accumbens shell.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14656311     DOI: 10.1111/j.1460-9568.2003.02961.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  27 in total

Review 1.  The neurocircuitry of addiction: an overview.

Authors:  M W Feltenstein; R E See
Journal:  Br J Pharmacol       Date:  2008-03-03       Impact factor: 8.739

2.  Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies.

Authors:  Ying Qu; Neal R Swerdlow; Martin Weber; David Stouffer; Loren H Parsons
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

Review 3.  The endocannabinoid system in brain reward processes.

Authors:  M Solinas; S R Goldberg; D Piomelli
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

Review 4.  Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors.

Authors:  Antonia Serrano; Loren H Parsons
Journal:  Pharmacol Ther       Date:  2011-07-18       Impact factor: 12.310

Review 5.  Systems level neuroplasticity in drug addiction.

Authors:  Matthew W Feltenstein; Ronald E See
Journal:  Cold Spring Harb Perspect Med       Date:  2013-05-01       Impact factor: 6.915

Review 6.  Drug addiction.

Authors:  Zuzana Justinova; Leigh V Panlilio; Steven R Goldberg
Journal:  Curr Top Behav Neurosci       Date:  2009

7.  CB1 antagonism: interference with affective properties of acute naloxone-precipitated morphine withdrawal in rats.

Authors:  Kiri L Wills; Kiran Vemuri; Alana Kalmar; Alan Lee; Cheryl L Limebeer; Alexandros Makriyannis; Linda A Parker
Journal:  Psychopharmacology (Berl)       Date:  2014-04-27       Impact factor: 4.530

8.  Endocannabinoid signaling in neurotoxicity and neuroprotection.

Authors:  C Pope; R Mechoulam; L Parsons
Journal:  Neurotoxicology       Date:  2009-12-05       Impact factor: 4.294

Review 9.  Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction.

Authors:  Leigh V Panlilio; Zuzana Justinova; Steven R Goldberg
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

10.  Individual differences in impulsive action and dopamine transporter function in rat orbitofrontal cortex.

Authors:  J R Yates; M Darna; J S Beckmann; L P Dwoskin; M T Bardo
Journal:  Neuroscience       Date:  2015-11-23       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.